Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1352173

Cover Image

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1352173

Global Coloboma Treatment Market - 2023-2030

PUBLISHED:
PAGES: 195 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4350
PDF & Excel (Multiple User License)
USD 4850
PDF & Excel (Enterprise License)
USD 7850

Add to Cart

Overview

The coloboma treatment market experiencing growth in recent years. The coloboma treatment market refers to the healthcare sector focusing on the diagnosis, management, and therapeutic interventions for coloboma, an eye disorder in which tissue is loosed or incomplete development of eye tissue affecting the various parts of the eye such as the iris, retina, optic nerve or choroid. There is no permanent cure for this eye disorder, but eyeglasses, contact lenses, surgery, and eye drops or eye patch are used for the management of coloboma.

Moreover, owing to the increasing prevalence of coloboma mainly in newborns, increasing research activities and clinical trials for better treatment, rising demand for telemedicine according to patient preference, increasing demand for novel contact lenses, and technological advancements in treatment options such as advanced contact lenses and eyewear are the major factors expected to drive the global coloboma market over the forecast period.

Dynamics

Rising Clinical Trials and Research Activities Drive the Growth of the Coloboma Treatment Market

The rising clinical trials and research activities are enhancing therapeutic innovations in the field of coloboma treatment. There is a continuous rising in clinical trials focusing on coloboma treatments by expanding the range of therapeutic options available to patients. These trials evaluate the safety and efficacy of novel interventions, ranging from surgical techniques to eye drops, and contact lenses. Positive clinical trial results increase innovative approvals for enhanced treatment. As more attention is increased on coloboma, research efforts are expanding to manage the unmet needs.

Moreover, there are continuous ongoing research and development activities that are leading to the development of more accurate and reliable diagnostic tools, and therapeutic innovations like advanced eye drops, and contact lenses for coloboma. Advanced imaging technologies enable earlier, easy, and more precise diagnosis of coloboma, allowing healthcare professionals to tailor treatment plans to individual patients.

Increasing Demand for Telemedicine Also Drives the Growth of the Coloboma Treatment Market

There is a growing demand for telemedicine in the field of coloboma treatment. Telemedicine offers a way for patients suffering from coloboma to access specialized medical care according to their preferences. This is particularly valuable for patients living in rural or poor areas without ophthalmology specialists or coloboma treatment centers. Telemedicine also eliminates the need for long travel distances, reducing the burden on patients and their families.

Telemedicine for coloboma patients also offers timely consultations and continuous monitoring with better results. Individuals, who are suffering from coloboma sometimes experience sudden changes in their vision, in such situations, they may require ophthalmology specialists, so they can easily consult through the telemedicine procedure in a comfortable way. Telemedicine also reduces appointment charges and time.

A Lack of Awareness About Coloboma and its Available Treatments Will Hamper the Growth of the Market

Awareness about coloboma and its available treatments is a key factor to consider, but there is a lack of awareness about the disease and its treatments, hampering the growth of the market. With a lack of awareness, individuals with coloboma do not recognize their associated symptoms early on or understand the importance of seeking medical attention. Delayed diagnosis can lead to missed opportunities for timely interventions, potentially resulting in irreversible vision impairment or complications.

Moreover, the lack of awareness can also leads to reduced patient, access, engagement, and participation in clinical trials, research studies, and treatment options due to unsafety concerns. Patients do not be proactive in seeking out information about the available treatments, leaving them unaware of potentially beneficial interventions.

Segment Analysis

The global coloboma treatment market is segmented based on type, treatment, end-user and region.

The Contact Lenses From the Treatment Segment Accounted for Approximately 39.2% of the Coloboma Treatment Market Share

There is no specific treatment for coloboma, but contact lenses play a crucial role in the management of coloboma, particularly when it affects the iris or leads to refractive errors. Coloboma can cause irregularities in the iris, leading to sensitivity to light known as photophobia and glare, to reduce this situation, contact lenses are mostly preferred. Mainly colored contact lenses can be used to reduce the amount of light entering the eye and improve visual comfort resulting in market dominance.

The individuals suffering from coloboma-related vision impairments, contact lenses are the most widely used and widely accepted and also can be used to optimize visual acuity. Specially designed contact lenses and colored contact lenses can help to focus light onto the retina, compensating for the abnormalities caused by the coloboma.

For instance, in April 2022, Johnson & Johnson Vision, a global leader in eye health, announced the launch of BUBBLE POP, a new range of colored contact lenses designed to meet the rising trend of makeovers among India's youth. The BUBBLE POP colored lenses are also used in vision management in coloboma patients.

Geographical Penetration

North America Accounted for Approximately 39.3% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Well-Established Healthcare Infrastructure

North America is home for its presence of major players such as pharmaceutical companies, medical device companies, contact lenses providers, and research activities. Several key companies in the ophthalmic and vision care sectors are majorly headquartered in North America, especially in the United States and Canada. These companies contribute significantly to market growth and research initiatives.

North America is known for its advanced and well-established healthcare infrastructure including eye hospitals and ophthalmic clinics. Regions advanced healthcare infrastructure helps to improve the patient's quality of life. The region is also dominated for its high expenditure and due to this advanced healthcare infrastructure, it is well-known research and development activity. For instance, according to the National Institute of Health, a coloboma prevalence of 0.5-0.7/10,000 live births are observed in North America annually.

Competitive Landscape

The major global players in the coloboma treatment market include: Alcon Vision LLC, Ziemer Ophthalmic Systems, Jawa Pharmaceuticals Pvt ltd, Bausch & Lomb, Carl Zeiss AG, Contamac Holdings Limited, Hoya Corporation, Johnson and Johnson Pvt Ltd, SynergEyes Inc., and CooperVision among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global coloboma treatment market. During the pandemic, research activities and clinical trials related to coloboma treatment products are temporarily disrupted due to the diversion towards COVID-19 research. Routine eye care services, including coloboma check-ups, diagnosis, and treatment, were often postponed or canceled, leading to delayed access to care for many individuals with coloboma.

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global coloboma treatment market, owing to the low prevalence due to the low population and the absence of key market players in this region. However, the impact of the import and export of raw materials such as contact lenses is expected to have little influence over the global coloboma treatment market growth over the forecast period.

By Type

  • Eyelid coloboma
  • Lens coloboma
  • Macular coloboma
  • Optic nerve coloboma
  • Uveal coloboma
  • Iris coloboma
  • Chorio-retinal coloboma

By Treatment

  • Eye Glasses
  • Contact Lenses
  • Surgery
  • Low Vision Aids
  • Eye Patch or Eye Drops

By End User

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global coloboma treatment market segmentation based on type, treatment, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of coloboma treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global coloboma treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
Product Code: PH6954

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Clinical Trials and Research Activities
      • 4.1.1.2. Rising Demand for Telemedicine
    • 4.1.2. Restraints
      • 4.1.2.1. A Lack of Awareness About Coloboma and its Available Treatments
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological Advancements in Treatment Options
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Eyelid coloboma *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Lens coloboma
  • 7.4. Macular coloboma
  • 7.5. Optic nerve coloboma
  • 7.6. Uveal coloboma
    • 7.6.1. Iris coloboma
    • 7.6.2. Chorio-retinal coloboma

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Eye Glasses *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Eye Glasses
  • 8.4. Contact Lenses
  • 8.5. Surgery
  • 8.6. Low Vision Aids
  • 8.7. Eye Patch or Eye Drops

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ophthalmic Clinics
  • 9.4. Ambulatory Surgical Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Alcon Vision LLC *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Ziemer Ophthalmic Systems
  • 12.3. Jawa Pharmaceuticals pvt ltd
  • 12.4. Bausch & Lomb
  • 12.5. Carl Zeiss AG
  • 12.6. Contamac Holdings Limited
  • 12.7. Hoya Corporation
  • 12.8. Johnson and Johnson Pvt Ltd
  • 12.9. SynergEyes Inc.
  • 12.10. CooperVision

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!